Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 10 | 2017 | 147 | 3.340 |
Why?
|
| Antibodies, Neutralizing | 7 | 2024 | 192 | 3.110 |
Why?
|
| Herpesvirus 8, Human | 5 | 2024 | 21 | 2.510 |
Why?
|
| Papillomavirus Infections | 6 | 2017 | 127 | 2.450 |
Why?
|
| Viral Envelope Proteins | 5 | 2024 | 111 | 2.350 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2024 | 92 | 2.240 |
Why?
|
| Herpesvirus 4, Human | 6 | 2024 | 184 | 2.200 |
Why?
|
| Papillomavirus Vaccines | 6 | 2015 | 72 | 2.070 |
Why?
|
| Viral Matrix Proteins | 5 | 2019 | 52 | 1.890 |
Why?
|
| Antibodies, Viral | 4 | 2024 | 304 | 1.670 |
Why?
|
| Sarcoma, Kaposi | 2 | 2024 | 17 | 1.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2015 | 747 | 1.180 |
Why?
|
| Macaca mulatta | 2 | 2024 | 246 | 1.050 |
Why?
|
| Papillomaviridae | 2 | 2017 | 60 | 1.040 |
Why?
|
| DNA, Viral | 3 | 2017 | 228 | 0.970 |
Why?
|
| Infectious Mononucleosis | 2 | 2022 | 35 | 0.910 |
Why?
|
| Cameroon | 8 | 2017 | 8 | 0.880 |
Why?
|
| Herpesviridae Infections | 2 | 2024 | 28 | 0.880 |
Why?
|
| Endothelial Cells | 2 | 2024 | 178 | 0.790 |
Why?
|
| Viral Proteins | 1 | 2024 | 261 | 0.780 |
Why?
|
| Mass Screening | 2 | 2017 | 664 | 0.730 |
Why?
|
| B-Lymphocytes | 4 | 2021 | 553 | 0.700 |
Why?
|
| Epithelial Cells | 2 | 2019 | 381 | 0.680 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 862 | 0.640 |
Why?
|
| Immunodominant Epitopes | 1 | 2019 | 57 | 0.640 |
Why?
|
| Early Detection of Cancer | 4 | 2017 | 276 | 0.640 |
Why?
|
| Viral Tropism | 1 | 2019 | 55 | 0.630 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2014 | 463 | 0.620 |
Why?
|
| Virion | 2 | 2019 | 123 | 0.600 |
Why?
|
| Fibroblasts | 1 | 2019 | 378 | 0.570 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2017 | 18 | 0.560 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2017 | 16 | 0.550 |
Why?
|
| Cancer Vaccines | 1 | 2017 | 48 | 0.550 |
Why?
|
| Mice, Inbred BALB C | 4 | 2024 | 879 | 0.550 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 67 | 0.540 |
Why?
|
| National Health Programs | 1 | 2016 | 14 | 0.530 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 74 | 0.530 |
Why?
|
| Birth Certificates | 1 | 2016 | 11 | 0.520 |
Why?
|
| Vaccination | 2 | 2019 | 342 | 0.510 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2015 | 2 | 0.490 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2015 | 29 | 0.480 |
Why?
|
| Genome, Viral | 2 | 2019 | 122 | 0.470 |
Why?
|
| Vaccinia virus | 2 | 2024 | 73 | 0.460 |
Why?
|
| Mice | 7 | 2024 | 10362 | 0.450 |
Why?
|
| Humans | 25 | 2024 | 60999 | 0.430 |
Why?
|
| Animals | 10 | 2024 | 19839 | 0.430 |
Why?
|
| Cell Line | 4 | 2024 | 2015 | 0.430 |
Why?
|
| Receptors, Complement 3b | 1 | 2013 | 13 | 0.420 |
Why?
|
| Virus Internalization | 3 | 2021 | 99 | 0.420 |
Why?
|
| Receptors, Complement 3d | 1 | 2013 | 18 | 0.420 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 240 | 0.410 |
Why?
|
| Alphapapillomavirus | 1 | 2013 | 17 | 0.410 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 700 | 0.410 |
Why?
|
| Awareness | 1 | 2013 | 76 | 0.400 |
Why?
|
| Fetal Proteins | 1 | 2012 | 12 | 0.400 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 972 | 0.400 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 141 | 0.390 |
Why?
|
| Female | 15 | 2024 | 31733 | 0.380 |
Why?
|
| Receptors, Immunologic | 1 | 2012 | 180 | 0.370 |
Why?
|
| Spleen | 1 | 2012 | 485 | 0.350 |
Why?
|
| Students | 1 | 2012 | 210 | 0.350 |
Why?
|
| HIV Infections | 1 | 2017 | 928 | 0.350 |
Why?
|
| Lepidoptera | 1 | 2009 | 10 | 0.330 |
Why?
|
| HEK293 Cells | 2 | 2024 | 588 | 0.310 |
Why?
|
| Parents | 1 | 2012 | 391 | 0.300 |
Why?
|
| Health Promotion | 1 | 2012 | 490 | 0.300 |
Why?
|
| Protein Binding | 3 | 2019 | 1585 | 0.280 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 761 | 0.280 |
Why?
|
| Cricetulus | 2 | 2017 | 101 | 0.270 |
Why?
|
| CHO Cells | 2 | 2017 | 191 | 0.270 |
Why?
|
| Colposcopy | 2 | 2017 | 22 | 0.260 |
Why?
|
| Immunization | 2 | 2017 | 132 | 0.250 |
Why?
|
| Kenya | 3 | 2016 | 83 | 0.240 |
Why?
|
| Adult | 8 | 2017 | 16226 | 0.240 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 437 | 0.240 |
Why?
|
| Castleman Disease | 1 | 2024 | 5 | 0.230 |
Why?
|
| Viral Vaccines | 1 | 2024 | 49 | 0.230 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 451 | 0.220 |
Why?
|
| Vaccines, DNA | 1 | 2024 | 98 | 0.220 |
Why?
|
| Amino Acid Sequence | 3 | 2019 | 1578 | 0.220 |
Why?
|
| Adolescent | 4 | 2016 | 6044 | 0.210 |
Why?
|
| Flow Cytometry | 1 | 2024 | 642 | 0.210 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 2083 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2015 | 344 | 0.200 |
Why?
|
| Serologic Tests | 1 | 2022 | 35 | 0.200 |
Why?
|
| Registries | 2 | 2016 | 811 | 0.190 |
Why?
|
| Prevalence | 2 | 2016 | 1321 | 0.190 |
Why?
|
| Sequence Alignment | 2 | 2019 | 294 | 0.190 |
Why?
|
| Cell Adhesion Molecules | 1 | 2021 | 85 | 0.180 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 78 | 0.180 |
Why?
|
| Capsid Proteins | 1 | 2021 | 93 | 0.180 |
Why?
|
| Research | 1 | 2022 | 195 | 0.180 |
Why?
|
| Child | 3 | 2016 | 4384 | 0.170 |
Why?
|
| Binding Sites, Antibody | 1 | 2019 | 28 | 0.160 |
Why?
|
| Hybridomas | 1 | 2019 | 65 | 0.160 |
Why?
|
| Binding, Competitive | 1 | 2019 | 100 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 2547 | 0.160 |
Why?
|
| Complementarity Determining Regions | 1 | 2019 | 37 | 0.160 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2019 | 183 | 0.160 |
Why?
|
| Young Adult | 3 | 2014 | 4433 | 0.160 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 135 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2019 | 360 | 0.160 |
Why?
|
| Rabbits | 1 | 2019 | 330 | 0.150 |
Why?
|
| Plasmids | 1 | 2019 | 284 | 0.150 |
Why?
|
| Genetic Vectors | 1 | 2024 | 818 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 459 | 0.150 |
Why?
|
| Mutation | 2 | 2019 | 2485 | 0.150 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 1389 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2019 | 228 | 0.150 |
Why?
|
| Vaccines, Inactivated | 1 | 2017 | 13 | 0.140 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 83 | 0.140 |
Why?
|
| Genomics | 1 | 2019 | 321 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 457 | 0.130 |
Why?
|
| Cricetinae | 1 | 2017 | 376 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 176 | 0.130 |
Why?
|
| Community Health Services | 1 | 2017 | 128 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2015 | 48 | 0.130 |
Why?
|
| Attitude | 1 | 2016 | 104 | 0.120 |
Why?
|
| Photography | 1 | 2015 | 43 | 0.120 |
Why?
|
| Africa | 1 | 2015 | 23 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 831 | 0.120 |
Why?
|
| Faculty | 1 | 2015 | 53 | 0.120 |
Why?
|
| Observer Variation | 1 | 2015 | 212 | 0.120 |
Why?
|
| Cervix Uteri | 1 | 2015 | 57 | 0.120 |
Why?
|
| Neutralization Tests | 1 | 2015 | 125 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2015 | 125 | 0.120 |
Why?
|
| Cell Adhesion | 1 | 2015 | 208 | 0.120 |
Why?
|
| Epidemiologic Factors | 1 | 2014 | 5 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Africa South of the Sahara | 1 | 2014 | 17 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 183 | 0.110 |
Why?
|
| Middle Aged | 3 | 2017 | 16872 | 0.110 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 29 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 670 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 9 | 0.110 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2013 | 8 | 0.110 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 20 | 0.110 |
Why?
|
| Genotype | 1 | 2015 | 652 | 0.100 |
Why?
|
| Virus Attachment | 1 | 2013 | 23 | 0.100 |
Why?
|
| K562 Cells | 1 | 2013 | 58 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 397 | 0.100 |
Why?
|
| Health Education | 1 | 2014 | 184 | 0.100 |
Why?
|
| Duffy Blood-Group System | 1 | 2012 | 2 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 63 | 0.100 |
Why?
|
| Neoplasms | 1 | 2022 | 1269 | 0.100 |
Why?
|
| Base Sequence | 2 | 2016 | 1310 | 0.100 |
Why?
|
| Temperature | 1 | 2013 | 302 | 0.090 |
Why?
|
| Schools | 1 | 2012 | 156 | 0.090 |
Why?
|
| Transfection | 1 | 2013 | 678 | 0.090 |
Why?
|
| Male | 4 | 2016 | 28463 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 491 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 860 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 796 | 0.080 |
Why?
|
| Synteny | 1 | 2009 | 24 | 0.080 |
Why?
|
| Open Reading Frames | 1 | 2009 | 81 | 0.080 |
Why?
|
| Aged | 2 | 2017 | 13876 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2009 | 82 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 2643 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 5288 | 0.070 |
Why?
|
| Pregnancy | 1 | 2014 | 2377 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1347 | 0.070 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 1976 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1550 | 0.060 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 10 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 1605 | 0.040 |
Why?
|
| Convalescence | 1 | 2016 | 18 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2108 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 76 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 229 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2016 | 252 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 675 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 346 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 238 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2016 | 370 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1088 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 757 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2015 | 6201 | 0.010 |
Why?
|